Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

Core Insights - Celcuity Inc. is set to release its financial results for Q3 2025 on November 12, 2025, after market close, followed by a webcast and teleconference at 4:30 p.m. Eastern Time [1] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for various solid tumor indications [3] - The lead therapeutic candidate, gedatolisib, is a potent pan-PI3K and mTORC1/2 inhibitor that blocks the PI3K/AKT/mTOR pathway comprehensively [3] - Celcuity's clinical trials include: - VIKTORIA-1: A Phase 3 trial evaluating gedatolisib with fulvestrant in HR+/HER2- ABC, which has completed enrollment and reported results for the PIK3CA Wild-Type cohort [3] - VIKTORIA-2: A Phase 3 trial currently enrolling patients, assessing gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- ABC [3] - CELC-G-201: A Phase 1/2 trial ongoing, evaluating gedatolisib with darolutamide in metastatic castration-resistant prostate cancer patients [3]